Recurrent Glioblastoma-Molecular Underpinnings and Evolving Treatment Paradigms.

Int J Mol Sci · 2024 · PMC11203521 · PMID 38928445

Europe PMC DOI

hedged sentence

0.0680

closest p · 1.4× alpha

0.0680

boldest claim

The sentences

did not reach statistical significancep = 0.068so close (0.05 < p ≤ 0.1)

reported that within the TTF monotherapy group, TTF improved the median PPS of recurrent glioblastoma patients with PTEN mutations, yet this improvement did not reach statistical significance (13.9 months versus 10.9 months, p = 0.068) [ 213 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.